<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04475380</url>
  </required_header>
  <id_info>
    <org_study_id>COASTLINE</org_study_id>
    <nct_id>NCT04475380</nct_id>
  </id_info>
  <brief_title>Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents</brief_title>
  <official_title>Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents (COASTLINE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Foundation of Cardiovascular Research and Education Enschede</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Foundation of Cardiovascular Research and Education Enschede</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Drug eluting stents (DES) are widely used for treatment of coronary artery lesions. The
      Xience Sierra stent has a refined design of the metal stent backbone and is used in patients
      with various clinical syndromes and in different lesions. Clinical outcome of patients with
      previously unknown (silent) diabetes and prediabetes is of increasing interest since the
      latter group has recently shown to be associated with a significant risk of adverse
      cardiovascular events after treatment with contemporary DES. Outcome data in a population of
      high-risk all-comer patients, including many patients with diabetes mellitus and prediabetes,
      would be of great interest, but such data are not available yet. In addition, there is a lack
      of data in a general all-comer population. Therefore, the COASTLINE study will primarily
      assess the safety and efficacy of the Xience Sierra stent in a general all-comer population
      as well as a high-risk all-comer population.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 21, 2018</start_date>
  <completion_date type="Anticipated">January 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Target vessel failure (TVF) at 1-year follow up in complex all-comers</measure>
    <time_frame>1 year</time_frame>
    <description>TVF is a composite endpoint consisting of cardiac death, target vessel related myocardial infarction, or clinically driven target vessel revascularization.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Target lesion failure (TLF) at 2-year follow up in all-comers</measure>
    <time_frame>2 year</time_frame>
    <description>TLF is a composite endpoint consisting of cardiac death, target vessel related myocardial infarction, or clinically driven target lesion revascularization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TVF at 2 year follow up</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>up to 3 year</time_frame>
    <description>any/cardiac/non-cardiac</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>up to 3 year</time_frame>
    <description>target vessel related/any/periprocedural</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically indicated target vessel revascularization</measure>
    <time_frame>up to 3 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically indicated target lesion revascularization</measure>
    <time_frame>up to 3 year</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1757</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Angina Pectoris</condition>
  <condition>Angina, Unstable</condition>
  <condition>Myocardial Infarction</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Stenosis</condition>
  <condition>Coronary Restenosis</condition>
  <arm_group>
    <arm_group_label>All-comer patients requiring PCI</arm_group_label>
    <description>All-comer patients requiring percutaneous coronary intervention (PCI) for the treatment of significant coronary artery of bypass graft lesions that are suitable for treatment with Xience Sierra DES</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Percutaneous coronary intervention</intervention_name>
    <description>PCI for treatment of coronary or bypass graft lesions</description>
    <arm_group_label>All-comer patients requiring PCI</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All-comers. Patients for elective PCI or acute PCI
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt;18 years

          -  requiring PCI and treated with Xience Sierra

          -  capable of providing informed consent

        Exclusion Criteria:

          -  known intolerance to components of the study DES or antithrombotic/anticoagulant
             therapy

          -  planned elective surgery necessitating interruption of dual antiplatelet therapy
             (DAPT) &lt; 3 months

          -  patient is known to be pregnant, unlikely to adhere to follow-up or expected live &lt; 1
             year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>C. von Birgelen, MD,PhD,Prof</last_name>
    <phone>0031534872105</phone>
    <email>cre@mst.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>M. Löwik, PhD</last_name>
    <phone>0031534872105</phone>
    <email>cre@mst.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Haga Ziekenhuis</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>C. Schotborgh, MD, PhD</last_name>
      <email>cardioresearch@hagaziekenhuis.nl</email>
    </contact>
    <investigator>
      <last_name>C. Schotborgh, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thoraxcentrum Twente</name>
      <address>
        <city>Enschede</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M. Löwik, PhD</last_name>
      <email>cre@mst.nl</email>
    </contact>
    <investigator>
      <last_name>C von Birgelen, MD,PhD,Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 14, 2020</study_first_submitted>
  <study_first_submitted_qc>July 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2020</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug-eluting stent</keyword>
  <keyword>Durable polymer</keyword>
  <keyword>Everolimus</keyword>
  <keyword>All comers population</keyword>
  <keyword>High-risk all comers</keyword>
  <keyword>Target vessel failure</keyword>
  <keyword>Coronary artery disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Coronary Stenosis</mesh_term>
    <mesh_term>Coronary Restenosis</mesh_term>
    <mesh_term>Angina, Unstable</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

